RU2005140664A - Просматривающий мутагенез - Google Patents

Просматривающий мутагенез Download PDF

Info

Publication number
RU2005140664A
RU2005140664A RU2005140664/13A RU2005140664A RU2005140664A RU 2005140664 A RU2005140664 A RU 2005140664A RU 2005140664/13 A RU2005140664/13 A RU 2005140664/13A RU 2005140664 A RU2005140664 A RU 2005140664A RU 2005140664 A RU2005140664 A RU 2005140664A
Authority
RU
Russia
Prior art keywords
library
polypeptide
amino acid
polynucleotides
region
Prior art date
Application number
RU2005140664/13A
Other languages
English (en)
Russian (ru)
Inventor
Роберто КРЕА (US)
Роберто КРЕА
Original Assignee
Байорен, Инк. (Us)
Байорен, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Байорен, Инк. (Us), Байорен, Инк. filed Critical Байорен, Инк. (Us)
Publication of RU2005140664A publication Critical patent/RU2005140664A/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1093—General methods of preparing gene libraries, not provided for in other subgroups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/005—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1282—Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
RU2005140664/13A 2003-06-27 2004-06-25 Просматривающий мутагенез RU2005140664A (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48328203P 2003-06-27 2003-06-27
US60/483,282 2003-06-27

Publications (1)

Publication Number Publication Date
RU2005140664A true RU2005140664A (ru) 2007-08-27

Family

ID=33563915

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2005140664/13A RU2005140664A (ru) 2003-06-27 2004-06-25 Просматривающий мутагенез

Country Status (14)

Country Link
US (1) US20050136428A1 (enExample)
EP (1) EP1660655B1 (enExample)
JP (2) JP4791960B2 (enExample)
KR (1) KR20060034650A (enExample)
CN (1) CN1836041A (enExample)
AU (1) AU2004254352A1 (enExample)
BR (1) BRPI0412007A (enExample)
CA (1) CA2542192C (enExample)
ES (1) ES2609102T3 (enExample)
IL (1) IL172736A0 (enExample)
NO (1) NO20060108L (enExample)
RU (1) RU2005140664A (enExample)
WO (1) WO2005003345A2 (enExample)
ZA (1) ZA200510460B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2748231C2 (ru) * 2016-01-08 2021-05-21 Момотаро-Джин Инк. Комбинированная терапия с использованием гена reic/dkk-3 и ингибитора контрольной точки иммунного ответа

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7329725B1 (en) * 2003-10-29 2008-02-12 Nastech Pharmaceutical Company Inc. Phage displayed Trp cage ligands
EP1781680B8 (en) 2004-07-06 2016-05-18 Bioren, LLC Universal antibody libraries
WO2006014477A1 (en) * 2004-07-06 2006-02-09 Bioren, Inc. HIGH AFFINITY ANTI-TNF-α ANTIBODIES AND METHOD
ATE528396T1 (de) 2004-07-06 2011-10-15 Bioren Inc Look-through-mutagenese zur entwicklung veränderter polypeptide mit verbesserten eigenschaften
WO2006094234A1 (en) * 2005-03-03 2006-09-08 Xencor, Inc. Methods for the design of libraries of protein variants
US20080207467A1 (en) * 2005-03-03 2008-08-28 Xencor, Inc. Methods for the design of libraries of protein variants
CA2605697A1 (en) * 2005-04-26 2006-11-02 Bioren, Inc. Method of producing human igg antibodies with enhanced effector functions
WO2007019620A1 (en) * 2005-08-15 2007-02-22 Arana Therapeutics Limited Engineered antibodies with new world primate framework regions
US8716195B2 (en) * 2005-11-14 2014-05-06 Bioren, Inc. Antibody ultrahumanization by predicted mature CDR blasting and cohort library generation and screening
US20110129414A1 (en) * 2005-11-15 2011-06-02 Balyasnikova Irina V Single Chain Fragment of Monoclonal Antibody 9B9 and Uses Thereof
US20090286962A1 (en) 2005-12-20 2009-11-19 Woolven Benjamin P Chimeric antibodies with part new world primate binding regions
NZ569988A (en) 2006-02-01 2011-09-30 Cephalon Australia Pty Ltd Domain antibody construct which binds to human TNF-alpha and contains a modified hinge region sequence and a truncated CH1 domain
US7704953B2 (en) * 2006-02-17 2010-04-27 Mdrna, Inc. Phage displayed cell binding peptides
US20070224627A1 (en) * 2006-03-23 2007-09-27 Lawrence Horowitz Facilitation of translocation of molecules through the gastrointestinal tract
JP2009537147A (ja) 2006-05-15 2009-10-29 シー レーン バイオテクノロジーズ， エルエルシー インフルエンザウイルスに対する中和抗体
WO2007136840A2 (en) * 2006-05-20 2007-11-29 Codon Devices, Inc. Nucleic acid library design and assembly
JP2010500876A (ja) 2006-08-18 2010-01-14 アブリンクス エン．ヴェー． Ｉｌ−６媒介性シグナル伝達に関連する疾患及び障害の治療のための、ｉｌ−６ｒに指向性を有するアミノ酸配列及びこれを含むポリペプチド
US8131480B2 (en) 2006-10-02 2012-03-06 Sea Lane Biotechnologies Llc Construction of diverse synthetic peptide and polypeptide libraries
WO2008045380A2 (en) * 2006-10-04 2008-04-17 Codon Devices, Inc. Nucleic acid libraries and their design and assembly
WO2008153925A2 (en) * 2007-06-06 2008-12-18 Danisco Us, Inc., Genencor Division Methods for improving multiple protein properties
WO2009009045A2 (en) * 2007-07-10 2009-01-15 The Scripps Research Institute Escape libraries of target polypeptides
US20090176654A1 (en) * 2007-08-10 2009-07-09 Protelix, Inc. Universal fibronectin type III binding-domain libraries
US8470966B2 (en) 2007-08-10 2013-06-25 Protelica, Inc. Universal fibronectin type III binding-domain libraries
US8680019B2 (en) * 2007-08-10 2014-03-25 Protelica, Inc. Universal fibronectin Type III binding-domain libraries
CA2706425A1 (en) 2007-11-27 2009-06-04 Ablynx N.V. Method for obtaining polypeptide constructs comprising two or more single domain antibodies
CA2719201A1 (en) 2008-03-28 2009-10-01 Sea Lane Biotechnologies, Llc. Neutralizing molecules to viral antigens
EP2131244A3 (en) * 2008-06-02 2012-04-11 ASML Netherlands BV Lithographic apparatus and method for measuring a pattern property
MX2011010681A (es) 2009-04-10 2012-01-20 Ablynx Nv Secuencias mejoradas de aminoacidos dirigidas contra il-6r y polipeptidos que comprenden el mismo para el tratamiento de enfermedades y trastornos relacionados con il-6r.
WO2010115995A2 (en) 2009-04-10 2010-10-14 Ablynx Nv Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of il-6r related diseases and disorders
CN102459332B (zh) 2009-06-05 2015-08-19 埃博灵克斯股份有限公司 用于预防和/或治疗呼吸道感染的单价、二价和三价抗人呼吸道合胞病毒(hrsv)纳米抗体构建体
SG10201700096VA (en) * 2009-07-17 2017-02-27 Bioatla Llc Simultaneous, Integrated Selection And Evolution Of Antibody/Protein Performance And Expression In Production Hosts
GB0914691D0 (en) * 2009-08-21 2009-09-30 Lonza Biologics Plc Immunoglobulin variants
US9139825B2 (en) 2009-10-30 2015-09-22 Novartis Ag Universal fibronectin type III bottom-side binding domain libraries
WO2011064382A1 (en) 2009-11-30 2011-06-03 Ablynx N.V. Improved amino acid sequences directed against human respiratory syncytial virus (hrsv) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections
AU2011283646B2 (en) 2010-07-30 2015-07-09 Novartis Ag Fibronectin cradle molecules and libraries thereof
JP5920835B2 (ja) 2010-12-01 2016-05-18 田辺三菱製薬株式会社 無細胞翻訳系でＦａｂを提示しうるポリヌクレオチド構築物ならびにそれを用いたＦａｂの製造方法およびスクリーニング方法
WO2013041722A1 (en) 2011-09-23 2013-03-28 Ablynx Nv Prolonged inhibition of interleukin-6 mediated signaling
JP6415987B2 (ja) 2012-03-02 2018-10-31 アブリンクス エン．ヴェー． シュードモナス・エルギノーサのＰｃｒＶに結合する単一可変ドメイン抗体
USRE49477E1 (en) * 2012-04-20 2023-03-28 Thomas Jefferson University Engineered antibody for inhibition of fibrosis
EP3929288A1 (en) 2012-05-25 2021-12-29 Chr. Hansen A/S Variants of chymosin with improved milk-clotting properties
WO2014087010A1 (en) 2012-12-07 2014-06-12 Ablynx N.V. IMPROVED POLYPEPTIDES DIRECTED AGAINST IgE
KR101600902B1 (ko) 2012-12-11 2016-03-10 주식회사 셀레믹스 코돈 조합화 및 변이유발을 이용한 유전자 라이브러리의 합성 방법
US20140314741A1 (en) * 2013-04-18 2014-10-23 Developmen Center For Biotechnology Human Antibody against Interleukin-20 and Treatment for Inflammatory Diseases
CA2924520C (en) * 2013-11-01 2023-09-26 Ibc Pharmaceuticals, Inc. Bispecific antibodies that neutralize both tnf-alpha and il-6: novel therapeutic agent for autoimmune disease
CN104805507B (zh) * 2014-01-29 2019-01-22 杭州康万达医药科技有限公司 噬菌体展示文库及其应用和制备方法
RU2739004C1 (ru) 2014-02-26 2020-12-21 Кхр. Хансен А/С Варианты химозина с улучшенными молокосвертывающими свойствами
CA2963712A1 (en) 2014-10-21 2016-04-28 Ablynx Nv Treatment of il-6r related diseases
EP3310914B1 (en) 2015-06-22 2022-04-06 Chr. Hansen A/S Variants of chymosin with improved properties
AU2016315269B2 (en) 2015-08-31 2021-09-23 Chr. Hansen A/S Variants of chymosin with improved properties
AR108526A1 (es) 2016-05-19 2018-08-29 Chr Hansen As Variantes de quimosina con propiedades mejoradas de coagulación de la leche
AR108527A1 (es) 2016-05-19 2018-08-29 Chr Hansen As Variantes de quimosina con propiedades mejoradas de coagulación de leche
CN117298260A (zh) * 2016-09-02 2023-12-29 莱蒂恩技术公司 用DuoCAR治疗癌症的组合物和方法
WO2019118918A1 (en) 2017-12-15 2019-06-20 Aleta Biotherapeutics Inc. Cd19 variants
CN117672369A (zh) * 2022-09-01 2024-03-08 珠海碳云智能科技有限公司 一种基于多肽芯片的抗体表位的高通量鉴定方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2079802C (en) * 1990-04-05 2001-09-18 Roberto Crea Walk-through mutagenesis
WO1995023813A1 (en) * 1994-03-04 1995-09-08 Merck & Co., Inc. In vitro antibody affinity maturation using alanine scanning mutagenesis
JP2003516755A (ja) * 1999-12-15 2003-05-20 ジェネンテック・インコーポレーテッド ショットガン走査、すなわち機能性タンパク質エピトープをマッピングするための組み合わせ方法

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2748231C2 (ru) * 2016-01-08 2021-05-21 Момотаро-Джин Инк. Комбинированная терапия с использованием гена reic/dkk-3 и ингибитора контрольной точки иммунного ответа
RU2767997C2 (ru) * 2016-01-08 2022-03-22 Момотаро-Джин Инк. КОМБИНИРОВАННАЯ ТЕРАПИЯ С ИСПОЛЬЗОВАНИЕМ ГЕНА REIC/Dkk-3 И ИНГИБИТОРА КОНТРОЛЬНОЙ ТОЧКИ ИММУННОГО ОТВЕТА

Also Published As

Publication number Publication date
EP1660655A2 (en) 2006-05-31
WO2005003345A3 (en) 2005-03-24
BRPI0412007A (pt) 2006-08-15
JP2007524390A (ja) 2007-08-30
JP5358604B2 (ja) 2013-12-04
JP4791960B2 (ja) 2011-10-12
CN1836041A (zh) 2006-09-20
US20050136428A1 (en) 2005-06-23
KR20060034650A (ko) 2006-04-24
EP1660655B1 (en) 2016-11-02
JP2011182794A (ja) 2011-09-22
AU2004254352A1 (en) 2005-01-13
CA2542192A1 (en) 2005-01-13
WO2005003345A2 (en) 2005-01-13
ES2609102T3 (es) 2017-04-18
IL172736A0 (en) 2006-04-10
CA2542192C (en) 2013-05-28
NO20060108L (no) 2006-03-24
ZA200510460B (en) 2006-11-29

Similar Documents

Publication Publication Date Title
CA2572917A1 (en) Look-through mutagenesis for developing altered polypeptides with enhanced properties
JP2011182794A5 (enExample)
Chao et al. A mammalian SRB protein associated with an RNA polymerase II holoenzyme
Li et al. Minimization of a polypeptide hormone
Goldman et al. Selection of phage displayed peptides for the detection of 2, 4, 6-trinitrotoluene in seawater
Hsu et al. Selective deamidation of recombinant human stem cell factor during in vitro aging: isolation and characterization of the aspartyl and isoaspartyl homodimers and heterodimers
CA2461571A1 (en) Muteins of human neutrophil gelatinase-associated lipocalin and related proteins
WO2003099999A3 (en) Generation and selection of protein library in silico
JP2008173124A (ja) Ｗｗドメインを有する新規ポリペプチドの同定と単離およびその利用方法
US20160054331A1 (en) Method for the detection and/or enrichment of analyte proteins and/or analyte peptides from a complex protein mixture
Jeffries et al. Small-angle X-ray scattering reveals the N-terminal domain organization of cardiac myosin binding protein C
US20090233812A1 (en) Target recognizing binding agents
CN106749527A (zh) 氯噻啉抗体特异性结合的噬菌体展示多肽及其用途
Pellegrini et al. Mapping the subsite preferences of protein tyrosine phosphatase PTP-1B using combinatorial chemistry approaches
US7091046B2 (en) Multiplexed protein expression and activity assay
Deshaies et al. Charting the protein complexome in yeast by mass spectrometry
Lee et al. Accurate MALDI-TOF/TOF Sequencing of One-Bead-One-Compound Peptide Libraries with Application to the Identification of Multi-ligand Protein Affinity Agents Using In Situ Click Chemistry Screening
Li et al. A rare monoclonal antibody discovery based on indirect competitive screening of a single hapten-specific rabbit antibody secreting cell
Zhao et al. A paradigm for drug discovery using a conformation from the crystal structure of a presentation scaffold
CN110256531A (zh) 吡虫啉抗体特异性结合的噬菌体展示多肽及其用途
Hekman et al. Isolation and identification of peptide degradation products of heat stressed pramlintide injection drug product
Svetlov et al. Rpb3, stoichiometry and sequence determinants of the assembly into yeast RNA polymerase II in vivo
Hara et al. Peptide map procedure using immobilized protease cartridges in tandem for disulfide linkage identification of neu differentiation factor epidermal growth factor domain
CN104987361B (zh) 苯噻菌酯抗体特异性结合的多肽及其用途
Napolitano et al. Glubodies: randomized libraries of glutathione transferase enzymes

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20071009